S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)

BELLUS Health - BLU Stock Forecast, Price & News

$9.83
+0.12 (+1.24%)
(As of 12/8/2022 02:43 PM ET)
Add
Compare
Today's Range
$9.72
$9.94
50-Day Range
$8.59
$10.76
52-Week Range
$4.98
$12.69
Volume
10,307 shs
Average Volume
604,914 shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

BELLUS Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
103.5% Upside
$20.00 Price Target
Short Interest
Bearish
7.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.74) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

499th out of 1,022 stocks

Pharmaceutical Preparations Industry

221st out of 499 stocks

BLU stock logo

About BELLUS Health (NASDAQ:BLU) Stock

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

RBC Capital Keeps Their Buy Rating on BELLUS Health (BLU)
TSX Ends Lower As Inflation Data Fuels Interest Rate Concerns
Expert Ratings for BELLUS Health
Bellus Health Inc stock raised on Friday.
Why BELLUS Health Stock Fell Today
Here's Why BELLUS Health Shares Are Diving Lower Today
BELLUS, Dollarama, Loblaw at 52-Week Highs
See More Headlines
Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Company Calendar

Last Earnings
11/10/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLU
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+103.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-71,220,000.00
Net Margins
-453,737.50%
Pretax Margin
-454,725.00%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
61,825.79
Book Value
$2.74 per share

Miscellaneous

Free Float
95,389,000
Market Cap
$1.24 billion
Optionable
Not Optionable
Beta
0.08

Key Executives

  • Mr. Roberto Francesco BelliniMr. Roberto Francesco Bellini (Age 42)
    Pres, CEO & Director
    Comp: $353.03k
  • Mr. Ramzi Benamar (Age 49)
    Chief Financial Officer
    Comp: $607.33k
  • Dr. Denis Garceau (Age 65)
    Chief Scientific Officer
    Comp: $431.87k
  • Mr. Tony Matzouranis (Age 49)
    Sr. VP of Bus. Devel.
    Comp: $272.89k
  • Dr. Catherine M. Bonuccelli M.D. (Age 64)
    Chief Medical Officer
    Comp: $703.77k
  • Dr. Andreas Orfanos FFPM (Age 63)
    M.B.B.Ch, MBA, Chief Operating Officer
  • Mr. Daniel Matthews
    Director of Investor Relations & Communications
  • Mr. Francois Desjardins C.A. (Age 59)
    CPA, CPA, CA, Sr. VP of Fin.
  • Mr. Sebastien Roy (Age 46)
    Corp. Sec.













BLU Stock - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLU shares.
View BLU analyst ratings
or view top-rated stocks.

What is BELLUS Health's stock price forecast for 2023?

5 Wall Street analysts have issued twelve-month price objectives for BELLUS Health's shares. Their BLU share price forecasts range from $18.00 to $21.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for BLU
or view top-rated stocks among Wall Street analysts.

How have BLU shares performed in 2022?

BELLUS Health's stock was trading at $8.05 at the beginning of 2022. Since then, BLU stock has increased by 21.4% and is now trading at $9.77.
View the best growth stocks for 2022 here
.

Are investors shorting BELLUS Health?

BELLUS Health saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,910,000 shares, a drop of 13.1% from the October 31st total of 11,410,000 shares. Based on an average trading volume of 610,200 shares, the days-to-cover ratio is currently 16.2 days.
View BELLUS Health's Short Interest
.

When is BELLUS Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BLU earnings forecast
.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative net margin of 453,737.50% and a negative trailing twelve-month return on equity of 23.37%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."

Who are BELLUS Health's major shareholders?

BELLUS Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.05%), Perceptive Advisors LLC (8.15%), Pictet Asset Management SA (6.65%), Commodore Capital LP (4.08%), Lynx1 Capital Management LP (1.89%) and First Light Asset Management LLC (1.89%).

How do I buy shares of BELLUS Health?

Shares of BLU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately $9.77.

How much money does BELLUS Health make?

BELLUS Health (NASDAQ:BLU) has a market capitalization of $1.23 billion and generates $20,000.00 in revenue each year. The company earns $-71,220,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The official website for the company is www.bellushealth.com. The company can be reached via phone at (450) 680-4500, via email at fdesjardins@bellushealth.com, or via fax at 45-0680-4501.

This page (NASDAQ:BLU) was last updated on 12/8/2022 by MarketBeat.com Staff